Trimidox (VF 233) is primarily used in research and experimental settings as a potent inhibitor of ribonucleotide reductase, an enzyme critical for DNA synthesis. By targeting this enzyme, it has shown potential in inhibiting the proliferation of cancer cells, making it a candidate for anticancer therapy studies. Its mechanism of action involves disrupting the production of deoxyribonucleotides, which are essential for DNA replication and repair. This property is particularly valuable in investigating treatments for rapidly dividing cells, such as those in tumors. Additionally, Trimidox has been explored in studies related to viral infections, where it may help in reducing viral replication by limiting the availability of nucleotides. Its application remains largely confined to preclinical research, focusing on understanding its efficacy and safety profile for potential therapeutic use.